Home
Clinical Resources Search
Advances in MRD Monitoring for Diffuse Large B-Cell Lymphoma (DLBCL)

Advances in MRD Monitoring for Diffuse Large B-Cell Lymphoma (DLBCL)

Download PQI pdf 0.24MB

Last Updated: May 5, 2025

By: Tara Graff, DO, MS

About this PQI

The purpose of this PQI is to assess an unmet need in the DLBCL patient population by enhancing the ability to evaluate treatment efficacy, monitor disease kinetics and remission, and detect early relapse.

How to Use a Positive Quality Intervention (PQI)

Essentially, it’s a tool to improve patient care by sharing best practices in oncology care. Consider this standardized, peer-review clinical guidance to oncology healthcare teams, enabling you and your team to consistently deliver high-quality care to your patients.

Find a PQI

Find Similar Resources

All Resources

PQI PQI in Action Treatment Support Kit Diffuse Large B-Cell Lymphoma (DLBCL) Minimal Risidual Disease (MRD)

PQI

Frequently Searched

Supported by

Advances in MRD Monitoring for Diffuse Large B-Cell Lymphoma (DLBCL)

About this PQI

How to Use a Positive Quality Intervention (PQI)

Find Similar Resources

Epcoritamab (Epkinly®) for Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma

PQI: Ibrutinib Dosing Optimization

PQI: Zanubrutinib (Brukinsa®) Patient Selection and Management

PQI: Zanubrutinib (Brukinsa ®) treatment for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

PQI in Action: Tremelimumab-actl (Imjudo®) Patient Management

PQI in Action: Tepotinib (Tepmetko®) for Non-Small Cell Lung Cancerwith MET Exon 14 Alterations

PQI in Action: Siltuximab (Sylvant®) in Patients with Idiopathic Multicentric Castleman Disease

PQI in Action: Isatuximab-irfc (Sarclisa®) in 1q21 Gain or Amplifications in Relapsed/Refractory Multiple Myeloma

Treatment Support Kit: Abemaciclib

Treatment Support Kit: Temozolomide

Treatment Support Kit: Tivozanib

Treatment Support Kit: Regorafenib

Epcoritamab (Epkinly®) for Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma

PQI: Tafasitamab-cxix (Monjuvi®) for Relapsed/Refractory Diffuse Large B-Cell Lymphoma

PQI: Selinexor (Xpovio®) Patient Management

PQI: Loncastuximab tesirine-lpyl (Zynlonta®) in Relapsed/Refractory Large B-Cell Lymphoma

PQI: clonoSEQ® Next Generation Sequencing for Minimum Residual Disease Testing in Chronic Lymphocytic Leukemia

PQI: clonoSEQ® Next Generation Sequencing for Minimal Residual Disease Testing in Multiple Myeloma

PQI in Action: ClonoSEQ® Next Generation Sequencing for Minimal Residual Disease Testing in Multiple Myeloma

Epcoritamab (Epkinly®) for Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma

The PQI Podcast S8 Bonus Episode: ¡No Más Melanomas! – Updates in the Treatment of Cutaneous Melanoma

S8 Ep 12: Lorlatinib in Practice: 5 Years of Data, Real-World Counseling, and AE Management

S8 Ep 11: Honoring Her Legacy: A Conversation with Miss America 2024